Am J Rhinol Allergy:过敏性鼻炎的症状与减少的健康生活品质的关系

2017-07-23 AlexYang MedSci原创

目前,特异性的过敏性鼻炎症状对病人生活品质(QOL)的影响仍旧未知。最近,有研究人员探究了过敏性鼻炎鼻骨和鼻外症状对健康相关的QOL的关系。该横断面研究总共包括了150名年龄大于18岁的参与者,并且这些参与者患有永久性过敏性鼻炎。健康相关的QOL通过利用来自5维EuroQol QOL调查(EO-5D)的视觉模拟量表(VAS)来进行测量。利用22项中鼻结果测试(SNOT-22)来对鼻骨和鼻外症状的严

目前,特异性的过敏性鼻炎症状对病人生活品质(QOL)的影响仍旧未知。最近,有研究人员探究了过敏性鼻炎鼻骨和鼻外症状对健康相关的QOL的关系。

该横断面研究总共包括了150名年龄大于18岁的参与者,并且这些参与者患有永久性过敏性鼻炎。健康相关的QOL通过利用来自5维EuroQol QOL调查(EO-5D)的视觉模拟量表(VAS)来进行测量。利用22项中鼻结果测试(SNOT-22)来对鼻骨和鼻外症状的严重度进行测量。利用鼻塞严重度评估(NOSE)表对鼻塞的严重度进行测量。另外,每位参与者完成鼻炎控制评估测试(RCAT)。

研究发现,SNOT-22总得分与RCAT((r = -0.68 [95% confidence interval {CI}, -0.75 to -0.58]; p < 0.001)和EQ-5D VAS(r = -0.44 [95% CI, -0.56 to -0.30]; p < 0.001)显著相关。在22项综合征评估中的SNOT-22、睡眠相关症状和耳症状与健康QOL的最大减少相关。鼻骨症状与健康相关的QOL关联度最小。鼻塞症状与健康相关QOL没有关联性(p=0.267)。另外,研究人员通过展现出NOSE得分与EO-5D VSA没有显著的相关项进一步确认了该发现。最后,研究人员指出,睡眠和耳症状对患有永久性过敏性鼻炎的成年人QOL具有最大的负面影响,并且应该在他们的临床评估中包括该两项内容。

原始出处:

Hoehle LP, Speth MM, Phillips KM et al. Association between symptoms of allergic rhinitis with decreased general health-related quality of life. Am J Rhinol Allergy. 1 July 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660899, encodeId=3adf1660899ee, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Sat Nov 25 07:46:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046859, encodeId=42972046859dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 20 13:46:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070866, encodeId=d5f320e086671, content=<a href='/topic/show?id=3f186913612' target=_blank style='color:#2F92EE;'>#生活品质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69136, encryptionId=3f186913612, topicName=生活品质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Nov 14 15:46:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328996, encodeId=1b501328996da, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 25 05:46:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225470, encodeId=471e2254e043, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Jul 23 15:47:11 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660899, encodeId=3adf1660899ee, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Sat Nov 25 07:46:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046859, encodeId=42972046859dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 20 13:46:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070866, encodeId=d5f320e086671, content=<a href='/topic/show?id=3f186913612' target=_blank style='color:#2F92EE;'>#生活品质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69136, encryptionId=3f186913612, topicName=生活品质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Nov 14 15:46:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328996, encodeId=1b501328996da, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 25 05:46:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225470, encodeId=471e2254e043, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Jul 23 15:47:11 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660899, encodeId=3adf1660899ee, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Sat Nov 25 07:46:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046859, encodeId=42972046859dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 20 13:46:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070866, encodeId=d5f320e086671, content=<a href='/topic/show?id=3f186913612' target=_blank style='color:#2F92EE;'>#生活品质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69136, encryptionId=3f186913612, topicName=生活品质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Nov 14 15:46:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328996, encodeId=1b501328996da, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 25 05:46:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225470, encodeId=471e2254e043, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Jul 23 15:47:11 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660899, encodeId=3adf1660899ee, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Sat Nov 25 07:46:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046859, encodeId=42972046859dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 20 13:46:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070866, encodeId=d5f320e086671, content=<a href='/topic/show?id=3f186913612' target=_blank style='color:#2F92EE;'>#生活品质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69136, encryptionId=3f186913612, topicName=生活品质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Nov 14 15:46:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328996, encodeId=1b501328996da, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 25 05:46:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225470, encodeId=471e2254e043, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Jul 23 15:47:11 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-25 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1660899, encodeId=3adf1660899ee, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Sat Nov 25 07:46:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046859, encodeId=42972046859dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 20 13:46:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070866, encodeId=d5f320e086671, content=<a href='/topic/show?id=3f186913612' target=_blank style='color:#2F92EE;'>#生活品质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69136, encryptionId=3f186913612, topicName=生活品质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Nov 14 15:46:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328996, encodeId=1b501328996da, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 25 05:46:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225470, encodeId=471e2254e043, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Jul 23 15:47:11 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 130****4638

    学习了受益匪浅

    0

相关资讯

Am J Physiol Lung C:组织胺和白介素-4在气道上皮中通过EMEM16A的协同黏液分泌

组织胺是一种重要的过敏反应调控子,并且黏液分泌过多是一种主要的过敏症状。然而,组织胺对气道粘膜上皮的黏液分泌的直接影响并没有很好的阐释。TMEM16A是一种Ca2+激活的氯离子通道,并且它与气道粘膜上皮的液体分泌密切相关。最近,有研究人员调查了是否组织胺直接从上皮细胞或者粘膜下腺体(SMG)诱导液体分泌,以及过敏气道疾病相关的机制。在来自鼻子或者器官的猪气道组织中,组织胺是一种强有力的促分泌素,并

Allergol Immunopathol (Madr):布达佩斯小学儿童过敏性鼻炎症状的流行和风险因子趋势

在匈牙利的学生中,有很少可用的数据涉及到学生的与过敏性鼻炎(AR)相关的时间变化趋势和风险因子。最近,研究人员进行了一项为期6年的研究。另外,6-12岁儿童的父母完成了基于ISAAC认证的和额外的关于可能风险因子的调查问卷。研究发现,在2007年,调查问卷为6335份,回复率为62.8%。在2013年,调查问卷数量为6441份,回复率为52.9%。目前AR症状(主体在过去的12个月中表现临床AR症

Tohoku J Exp Med:过敏性鼻炎鼻粘膜差异表达长非编码RNAs的鉴定和功能分析

之前的研究表明,长非编码RNAs(lncRNAs)在人类许多免疫疾病中起着重要的作用。然而,它们对过敏性鼻炎(AR)病理的影响还没有完全被人们理解。最近,有研究人员通过lncRNA基因芯片技术对过敏性鼻炎病人的鼻粘膜中lncRNA的表达进行了分析,还通过lncRNA-mRNA共表达网络、基因本体(GO)和信号途径分析预测了过敏性鼻炎病理机制中潜在的特异lncRNA的角色。研究结果表明,lncRNA

Mol Med Rep:TNFSF4与BLK基因多样性的关系以及对过敏性鼻炎的易感性

过敏性鼻炎(AR)是上呼吸道常见的炎症疾病。最近的证据表明,肿瘤坏死因子受体超家族4(TNFSF4)和B淋巴细胞激酶(BLK)基因间的互作也许在决定免疫失常方面的T和B细胞具有协同影响,并通过核转录因子κB信号通路。最近,有研究人员在中国人口中对AR敏感的人群中评估了TNFSF4和BKL基因中特异性单核苷酸多态(SNPs)的潜在联系。该研究是一个基于群体的且具有案例-对照的研究,包括了600名AR

Rhinology:在一个过敏性鼻炎小鼠模型中,过敏性炎症可以被过敏原诱导的类型2固有淋巴细胞加重

类型2固有淋巴细胞(ILC2s)代表了一种新的先天性效应白细胞类群,并且可以调节类型2免疫响应。然而,ILC2s对过敏性鼻炎(AR)的作用到目前为止仍旧还未鉴定。为了评估过敏原诱导的ILC2s在实验性AR中潜在的存在和作用,研究人员利用卵清蛋白(OVA)和氢氧化铝建立了一个AR小鼠模型,并从小鼠鼻相关淋巴组织(NALT)中筛选和纯化OVA诱导的ILC2s。然后,研究人员评估了在细胞培养中评估了IL

Ear Nose Throat J.:偏头痛和过敏性鼻炎之间有联系吗?

最近,来自土耳其的专家在Ear Nose Throat J上发表了一篇文章,研究了偏头痛与过敏性鼻炎的关系。 该研究是一项前瞻性研究,通过评估鼻症状和体征和进行过敏原特异性免疫球蛋白E(IgE)测试来调查偏头痛与过敏性鼻炎的关系。研究纳入了40名被诊断为偏头痛的患者,包括22名男性和18名女性,年龄范围为21至38岁(平均25.7岁)。研究人员将他们的结果与一个对照组相比较。对照组为40